Stage 0

31:33

Web Chat with the Expert series on Advances in Treatment Decision Making for Patients with Ductal Carcinoma in Situ (DCIS). Question and Answer session.

0:39

Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, says that DCIS breast cancer patients who have had a lumpectomy are eligible for the Oncotype DX DCIS Score.

1:22

In this video from the National Comprehensive Cancer Network (NCCN), breast cancer surgeon Stephen Edge, MD, Chair of Breast and Soft Tissue Surgery at Roswell Park Cancer Institute, explains how ductal carcinoma in situ (DCIS) is different from invasive breast cancer and why women with ductal carcinoma in situ usually do not get chemotherapy. The NCCN is a not-for-profit alliance of 21 leading cancer centers—including Roswell Park Cancer Institute—dedicated to improving care for cancer patients. You can find more information on breast cancer in the NCCN Guidelines for Patients with Breast Cancer, available at www.NCCN.com. These guidelines, part of the NCCN Guidelines for Patients series, discuss most types of breast cancer along with treatment options.

4:23

In this video, Dr. Eric Winer, Director of the Breast Oncology Program and one of the leaders of the Susan F. Smith Center for Women's Cancers at Dana-Farber, shares the definition of DCIS, weighs in on whether or not DCIS is considered cancer, and describes treatment options for women with DCIS. Learn more about how Dana-Farber's physicians treat breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce....

at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce....

Advertisement